172 related articles for article (PubMed ID: 34867735)
1. Is Generalized and Segmental Dystonia Accompanied by Impairments in the Dopaminergic System?
Ikezawa J; Yokochi F; Okiyama R; Kumada S; Tojima M; Kamiyama T; Hanakawa T; Matsuda H; Tanaka F; Nakata Y; Isozaki E
Front Neurol; 2021; 12():751434. PubMed ID: 34867735
[No Abstract] [Full Text] [Related]
2. Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease.
Isaias IU; Trujillo P; Summers P; Marotta G; Mainardi L; Pezzoli G; Zecca L; Costa A
Front Aging Neurosci; 2016; 8():196. PubMed ID: 27597825
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of the substantia nigra echogenicity and
Mašková J; Školoudík D; Štofaniková P; Ibarburu V; Kemlink D; Zogala D; Trnka J; Krupička R; Šonka K; Růžička E; Dušek P
Sleep Med; 2020 Jun; 70():116-123. PubMed ID: 32403038
[TBL] [Abstract][Full Text] [Related]
4. Principal Component Analysis of Multimodal Neuromelanin MRI and Dopamine Transporter PET Data Provides a Specific Metric for the Nigral Dopaminergic Neuronal Density.
Kawaguchi H; Shimada H; Kodaka F; Suzuki M; Shinotoh H; Hirano S; Kershaw J; Inoue Y; Nakamura M; Sasai T; Kobayashi M; Suhara T; Ito H
PLoS One; 2016; 11(3):e0151191. PubMed ID: 26954690
[TBL] [Abstract][Full Text] [Related]
5. Motor Progression and Nigrostriatal Neurodegeneration in Parkinson Disease.
Furukawa K; Shima A; Kambe D; Nishida A; Wada I; Sakamaki H; Yoshimura K; Terada Y; Sakato Y; Mitsuhashi M; Sawamura M; Nakanishi E; Taruno Y; Yamakado H; Fushimi Y; Okada T; Nakamoto Y; Takahashi R; Sawamoto N
Ann Neurol; 2022 Jul; 92(1):110-121. PubMed ID: 35428994
[TBL] [Abstract][Full Text] [Related]
6. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
[TBL] [Abstract][Full Text] [Related]
7. Neuromelanin or DaT-SPECT: which is the better marker for discriminating advanced Parkinson's disease?
Okuzumi A; Hatano T; Kamagata K; Hori M; Mori A; Oji Y; Taniguchi D; Daida K; Shimo Y; Yanagisawa N; Nojiri S; Aoki S; Hattori N
Eur J Neurol; 2019 Nov; 26(11):1408-1416. PubMed ID: 31136060
[TBL] [Abstract][Full Text] [Related]
8. Neuromelanin magnetic resonance imaging of substantia nigra and locus coeruleus in Parkinson's disease with freezing of gait.
Wang S; Wu T; Cai Y; Yu Y; Chen X; Wang L
Front Aging Neurosci; 2023; 15():1060935. PubMed ID: 36819729
[TBL] [Abstract][Full Text] [Related]
9. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
[TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease multimodal imaging: F-DOPA PET, neuromelanin-sensitive and quantitative iron-sensitive MRI.
Depierreux F; Parmentier E; Mackels L; Baquero K; Degueldre C; Balteau E; Salmon E; Phillips C; Bahri MA; Maquet P; Garraux G
NPJ Parkinsons Dis; 2021 Jul; 7(1):57. PubMed ID: 34238927
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
[TBL] [Abstract][Full Text] [Related]
12. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.
Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480
[TBL] [Abstract][Full Text] [Related]
13. Transcranial sonography of the substantia nigra and its correlation with DAT-SPECT in the diagnosis of Parkinson's disease.
Li DH; Zhang LY; Hu YY; Jiang XF; Zhou HY; Yang Q; Kang WY; Liu J; Chen SD
Parkinsonism Relat Disord; 2015 Aug; 21(8):923-8. PubMed ID: 26066091
[TBL] [Abstract][Full Text] [Related]
14. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts.
Kraemmer J; Kovacs GG; Perju-Dumbrava L; Pirker S; Traub-Weidinger T; Pirker W
Mov Disord; 2014 Dec; 29(14):1767-73. PubMed ID: 25048738
[TBL] [Abstract][Full Text] [Related]
15. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease.
He N; Ghassaban K; Huang P; Jokar M; Wang Y; Cheng Z; Jin Z; Li Y; Sethi SK; He Y; Chen Y; Gharabaghi S; Chen S; Yan F; Haacke EM
Neuroimage; 2021 Apr; 230():117810. PubMed ID: 33524572
[TBL] [Abstract][Full Text] [Related]
16. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
[TBL] [Abstract][Full Text] [Related]
17. Dilated Perivascular Space in the Midbrain May Reflect Dopamine Neuronal Degeneration in Parkinson's Disease.
Li Y; Zhu Z; Chen J; Zhang M; Yang Y; Huang P
Front Aging Neurosci; 2020; 12():161. PubMed ID: 32581771
[No Abstract] [Full Text] [Related]
18. Substantia nigra neuromelanin magnetic resonance imaging in patients with different subtypes of Parkinson disease.
Wang L; Yan Y; Zhang L; Liu Y; Luo R; Chang Y
J Neural Transm (Vienna); 2021 Feb; 128(2):171-179. PubMed ID: 33559725
[TBL] [Abstract][Full Text] [Related]
19. Magnetic Susceptibility Associates With Dopaminergic Deficits and Cognition in Parkinson's Disease.
Uchida Y; Kan H; Sakurai K; Inui S; Kobayashi S; Akagawa Y; Shibuya K; Ueki Y; Matsukawa N
Mov Disord; 2020 Aug; 35(8):1396-1405. PubMed ID: 32369660
[TBL] [Abstract][Full Text] [Related]
20. Substantia nigra echogenicity: A structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease.
Weise D; Lorenz R; Schliesser M; Schirbel A; Reiners K; Classen J
Mov Disord; 2009 Aug; 24(11):1669-75. PubMed ID: 19514075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
